ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Compass Therapeutics debuts with $132 million in funding

by Lisa Jarvis
July 13, 2018 | APPEARED IN VOLUME 96, ISSUE 29

 

Compass Therapeutics has raised a total of $132 million in its first formal round of financing. The Cambridge, Mass.-based biotech firm was formed in 2014 to capitalize on a bispecific antibody screening platform that allows it to probe the activity of combinations of immune cells. It also boasts a discovery platform that swiftly yields therapeutics—either monoclonal or bispecific antibodies. Compass has more than 70 employees and expects to begin clinical studies of its most advanced drug candidate, an antibody against an undisclosed immuno-oncology target, in the first half of 2019.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment